Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTT-251 in Heart Failure with Reduced Ejection Fraction (Phase 2)
2017-005093-19Phase 2Terminated
- Sponsor
- Akros Pharma Inc.
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing JTT-251 with Placebo (2 arms). Started Nov 2018; status: terminated.
02
Drugs
JTT-251
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2017-005093-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005093-19.